News and Insights
Universal cancer screening can be a powerful tool to help identify patients with genetic predispositions towards cancer. Cancers identified and treated at an early stage are more likely to have positive outcomes, using less invasive and less toxic …
For patients with complex health conditions, delivering better health outcomes depends on close coordination between primary care providers and specialists. Yet, our traditional healthcare system often makes such collaboration extremely difficulty, says …
While value-based care efforts over the last decade have focused on primary care — growing and maturing ACOs — the spotlight is turning to specialty care for the future, says Kamal Golla, Evolent’s senior medical director of value transformation. …
Predicting health risks, streamlining clinician administrative tasks, and leveraging data to drive better health outcomes across communities are just a few ways that AI is transforming patient care and population health — but we’re still in the early …
Clinical trial participants tend to be healthier, younger and less diverse than the general population. That’s one likely reason that, after new drugs reach the market, outcomes in real-world patients often fall short of those seen in trials. In a …
The evidence supports hypofractionation in many cancer treatment scenarios, but there are still many missed opportunities. Shortened courses of radiation therapy offer potential advantages for both patients and payers. Prominent medical societies have …
Evolent program achieves 20% reduction in use of low-value oncology regimens …
Cardiotoxicity is heart damage that can come from certain cancer treatments, either during treatment or years after it. This includes cardiomyopathy, which makes it more difficult for the heart to pump blood, as well as heart failure, coronary artery …
According to National Comprehensive Cancer Network guidelines, every patient diagnosed with ovarian cancer should undergo genetic testing, which can help guide treatment selection. Yet, an analysis found that just slightly more than half of these patients …
PD-L1 inhibitors have changed the paradigm for treatment of many cancers. For certain patients — like those with metastasized malignant melanoma — these immunotherapy drugs have offered the potential for a cure. Yet, across the cancer treatment landscape …